IL138284A0 - Acylbenzoxazines for enhancing synaptic response(s) - Google Patents

Acylbenzoxazines for enhancing synaptic response(s)

Info

Publication number
IL138284A0
IL138284A0 IL13828499A IL13828499A IL138284A0 IL 138284 A0 IL138284 A0 IL 138284A0 IL 13828499 A IL13828499 A IL 13828499A IL 13828499 A IL13828499 A IL 13828499A IL 138284 A0 IL138284 A0 IL 138284A0
Authority
IL
Israel
Prior art keywords
ampa receptors
enhancing
treatment
methods
acylbenzoxazines
Prior art date
Application number
IL13828499A
Other languages
English (en)
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Publication of IL138284A0 publication Critical patent/IL138284A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IL13828499A 1998-04-03 1999-04-02 Acylbenzoxazines for enhancing synaptic response(s) IL138284A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/054,916 US6124278A (en) 1998-04-03 1998-04-03 Acylbenzoxazines for enhancing synaptic response
PCT/US1999/007325 WO1999051240A1 (en) 1998-04-03 1999-04-02 Acylbenzoxazines for enhancing synaptic response(s)

Publications (1)

Publication Number Publication Date
IL138284A0 true IL138284A0 (en) 2001-10-31

Family

ID=21994357

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13828499A IL138284A0 (en) 1998-04-03 1999-04-02 Acylbenzoxazines for enhancing synaptic response(s)

Country Status (22)

Country Link
US (1) US6124278A (cs)
EP (1) EP1067935B1 (cs)
JP (1) JP4574846B2 (cs)
KR (1) KR100646753B1 (cs)
CN (1) CN1186020C (cs)
AT (1) ATE247472T1 (cs)
BR (1) BR9909378A (cs)
CA (1) CA2326764C (cs)
CZ (1) CZ292931B6 (cs)
DE (1) DE69910552T2 (cs)
DK (1) DK1067935T3 (cs)
ES (1) ES2207194T3 (cs)
HK (1) HK1039060B (cs)
HU (1) HUP0102321A3 (cs)
IL (1) IL138284A0 (cs)
NO (1) NO20004383L (cs)
NZ (1) NZ506712A (cs)
PL (1) PL195394B1 (cs)
PT (1) PT1067935E (cs)
RU (1) RU2246498C2 (cs)
TR (1) TR200002849T2 (cs)
WO (1) WO1999051240A1 (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI232863B (en) 2001-06-11 2005-05-21 Akzo Nobel Nv Benzoxazepine derivatives
IL158928A0 (en) 2001-06-14 2004-05-12 Akzo Nobel Nv (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES
PL371722A1 (en) * 2001-11-26 2005-06-27 Cortex Pharmaceuticals, Inc. Carbonylbenzoxazine compounds for enhancing glutamatergic synaptic responses
WO2009019032A2 (en) * 2003-08-08 2009-02-12 Dsm Ip Assets B.V. Novel method for screening brain-active compounds
TW200800959A (en) 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
CL2008000119A1 (es) 2007-01-16 2008-05-16 Wyeth Corp Compuestos derivados de pirazol, antagonistas del receptor nicotinico de acetilcolina; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como demencia senil, alzheimer y esquizofrenia.
CA2726554C (en) * 2008-06-06 2015-02-24 Sanofi-Aventis Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
US20110218190A1 (en) * 2008-11-10 2011-09-08 The Regents Of The University Of California Therapeutic uses of ampa receptor modulators for treatment of motor dysfunction
CN105579575A (zh) 2013-06-13 2016-05-11 维罗技术有限责任公司 用于治疗代谢失调的组合物和方法
CN108689876B (zh) * 2018-06-28 2020-11-27 苏州东南药业股份有限公司 一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0475908A1 (de) * 1990-09-14 1992-03-18 Ciba-Geigy Ag Chromogene Lactamverbindungen und ihre Herstellung und Verwendung
CA2450801C (en) * 1992-07-24 2009-11-17 The Regent Of The University Of California Drugs that enhance synaptic responses mediated by ampa receptors
US5650409A (en) * 1995-06-02 1997-07-22 Cortex Pharmaceuticals, Inc. Benzoyl piperidines/pyrrolidines for enhancing synaptic response
US5736543A (en) * 1996-04-03 1998-04-07 The Regents Of The University Of California Benzoxazines for enhancing synaptic response
US5985871A (en) * 1997-12-24 1999-11-16 Cortex Pharmaceuticals, Inc. Benzoxazine compounds for enhancing synaptic response

Also Published As

Publication number Publication date
AU3379899A (en) 1999-10-25
NZ506712A (en) 2002-11-26
CN1306427A (zh) 2001-08-01
JP2002510635A (ja) 2002-04-09
NO20004383L (no) 2000-10-09
AU736376B2 (en) 2001-07-26
JP4574846B2 (ja) 2010-11-04
ES2207194T3 (es) 2004-05-16
EP1067935A1 (en) 2001-01-17
HUP0102321A3 (en) 2002-01-28
HK1039060B (zh) 2005-05-13
KR100646753B1 (ko) 2006-11-17
NO20004383D0 (no) 2000-09-04
TR200002849T2 (tr) 2001-06-21
CZ292931B6 (cs) 2004-01-14
EP1067935B1 (en) 2003-08-20
PT1067935E (pt) 2004-01-30
CA2326764A1 (en) 1999-10-14
DK1067935T3 (da) 2003-11-24
DE69910552T2 (de) 2004-06-17
RU2246498C2 (ru) 2005-02-20
WO1999051240A8 (en) 2001-03-22
PL195394B1 (pl) 2007-09-28
HUP0102321A2 (hu) 2001-11-28
BR9909378A (pt) 2000-12-05
CZ20003614A3 (cs) 2001-01-17
DE69910552D1 (de) 2003-09-25
ATE247472T1 (de) 2003-09-15
CN1186020C (zh) 2005-01-26
KR20010042192A (ko) 2001-05-25
CA2326764C (en) 2010-12-14
PL345687A1 (en) 2002-01-02
EP1067935A4 (en) 2001-10-04
US6124278A (en) 2000-09-26
HK1039060A1 (en) 2002-04-12
WO1999051240A1 (en) 1999-10-14

Similar Documents

Publication Publication Date Title
AU2427497A (en) Benzoxazines for enhancing synaptic response
CA2138533A1 (en) Drugs that enhance synaptic responses mediated by ampa receptors
PL323667A1 (en) Benzoylopiperidines/benzoylopyrolydines for amplifying synaptic response
IL136783A (en) Synaptic response enhancing benzoxazine compounds,their preparation and pharmaceutical compositions containing them
ATE194593T1 (de) 3-(3,4-dioxyphenyl)-pyrrolidine als inhibitonen der typ iv - phosphodiesterase zur behandlung von entzündungskrankheiten
IL138284A0 (en) Acylbenzoxazines for enhancing synaptic response(s)
DK0751939T3 (da) Naphthylamider som centralnervesystemmidler
GB2325225A (en) Benzofurazan compounds for enhancing glutamatergic synaptic responses
EA200400584A1 (ru) Соединения карбонилбензоксазина для усиления глутаматергических синаптических ответов

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees